Literature DB >> 15277786

Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis.

Roberto Corti1, Randolph Hutter, Juan Jose Badimon, Valentin Fuster.   

Abstract

Recent developments into antherothrombosis, the leading cause of morbidity and mortality in Western Society, may help to change our treatment strategy to a more casual approach. The composition of the atherosclerotic plaque, rather than the percent stenosis, appears to be a critical predictor for both risk of plaque rupture and subsequent thrombogenicity. A large lipid core, rich in tissue factor (TF) and inflammatory cells including macrophages, and a thin fibrous cap with compromise of its structural integrity by matrix degrading enzymes, such as metalloproteinases (MMPs), render a lesion susceptible to rupture and subsequent acute thrombosis. Thrombosis may lead to a complete occlusion or, in the case of mural thrombus or intraplaque hemorrhage, to plaque progression. Disruption of a vulnerable or unstable plaque (type IV and Va lesions of the AHA classification) with a subsequent change in plaque geometry and thrombosis may result in an acute coronary syndrome. The high-risk plaque tend to be relatively small, but soft or vulnerable to "passive" disruption because of high lipid content. Inflammatory processes are important components of all stages of atherosclerotic development, including plaque initiation and disruption. As such the early steps in atherosclerotic lesion formation are the over expression of endothelial adhesive protein (i.e. selectins, VCAM and ICAM), chemotactic factors (MCP-1), growth factors (M-CSF), and cytokines (IL-2) that will facilitate the recruitment, internalization and survival of blood-borne inflammatory cells into the vascular wall. Macrophages, following what appears to be a defense mission by protecting the vessel wall from excess lipid accumulation, may eventually undergo apoptosis with release of MMPs and TF. Specific cell recruitment in the vessel wall and build-up of the extracellular matrix are coordinated by a wide variety of stimulators and inhibitors. Active interaction of immune competent cells within the atherosclerotic lesions appears to play a pivotal role in the control of atherosclerotic plaque evolution and, therefore, deserves particular attention from the research community with the ultimate goal of improving preventive and therapeutic medical approaches. Inflammation, thrombosis and atherosclerosis are interdependent and define a triad within the complex pathogenic process of atherothrombosis.

Entities:  

Mesh:

Year:  2004        PMID: 15277786     DOI: 10.1023/B:THRO.0000036027.39353.70

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  44 in total

Review 1.  Cellular adhesion molecules and atherogenesis.

Authors:  D T Price; J Loscalzo
Journal:  Am J Med       Date:  1999-07       Impact factor: 4.965

2.  Contrasting outcomes of atheroma evolution: intimal accumulation versus medial destruction.

Authors:  J B Michel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-09       Impact factor: 8.311

Review 3.  Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant.

Authors:  S Sartore; A Chiavegato; E Faggin; R Franch; M Puato; S Ausoni; P Pauletto
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

4.  Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina.

Authors:  H Soejima; H Ogawa; H Yasue; K Kaikita; K Nishiyama; K Misumi; K Takazoe; Y Miyao; M Yoshimura; K Kugiyama; S Nakamura; I Tsuji; K Kumeda
Journal:  Circulation       Date:  1999-06-08       Impact factor: 29.690

5.  Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins.

Authors:  U Rauch; J I Osende; J H Chesebro; V Fuster; D A Vorchheimer; K Harris; P Harris; D A Sandler; J T Fallon; S Jayaraman; J J Badimon
Journal:  Atherosclerosis       Date:  2000-11       Impact factor: 5.162

6.  Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.

Authors:  J J Badimon; M Lettino; V Toschi; V Fuster; M Berrozpe; J H Chesebro; L Badimon
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

7.  Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes.

Authors:  P R Moreno; V H Bernardi; J López-Cuéllar; A M Murcia; I F Palacios; H K Gold; R Mehran; S K Sharma; Y Nemerson; V Fuster; J T Fallon
Journal:  Circulation       Date:  1996-12-15       Impact factor: 29.690

8.  Tissue factor expression on macrophages in coronary plaques in patients with unstable angina.

Authors:  K Kaikita; H Ogawa; H Yasue; M Takeya; K Takahashi; T Saito; K Hayasaki; K Horiuchi; A Takizawa; Y Kamikubo; S Nakamura
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

9.  Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.

Authors:  A P Burke; A Farb; G T Malcom; Y H Liang; J Smialek; R Virmani
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

10.  Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture.

Authors:  A Fernández-Ortiz; J J Badimon; E Falk; V Fuster; B Meyer; A Mailhac; D Weng; P K Shah; L Badimon
Journal:  J Am Coll Cardiol       Date:  1994-06       Impact factor: 24.094

View more
  32 in total

Review 1.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

2.  Abnormal myocardial perfusion in the absence of anatomically significant coronary artery disease: implications and clinical significance.

Authors:  Shreenidhi M Venuraju; Ajay Yerramasu; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2009-09-10       Impact factor: 5.952

Review 3.  A systems biology approach to understanding atherosclerosis.

Authors:  Stephen A Ramsey; Elizabeth S Gold; Alan Aderem
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

4.  Changes in Plasma Protein Expression Indicative of Early Diet-induced Metabolic Disease in Male Pigs (Sus scrofa).

Authors:  Marinus Fw Te Pas; Sietse-Jan Koopmans; Leo Kruijt; Sjef Boeren; Mari A Smits
Journal:  Comp Med       Date:  2018-07-31       Impact factor: 0.982

5.  Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway.

Authors:  Wen-chin Ko; Bing-chang Chen; Ming-jen Hsu; Chia-ti Tsai; Chuang-ye Hong; Chien-huang Lin
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

6.  Quantifying effects of plaque structure and material properties on stress distributions in human atherosclerotic plaques using 3D FSI models.

Authors:  Dalin Tang; Chun Yang; Jie Zheng; Pamela K Woodard; Jeffrey E Saffitz; Gregorio A Sicard; Thomas K Pilgram; Chun Yuan
Journal:  J Biomech Eng       Date:  2005-12       Impact factor: 2.097

Review 7.  The Biology of Hemodialysis Vascular Access Failure.

Authors:  Akshaar Brahmbhatt; Sanjay Misra
Journal:  Semin Intervent Radiol       Date:  2016-03       Impact factor: 1.513

8.  Thrombophilia and arteriovenous fistula survival in ESRD.

Authors:  Birgitta Salmela; Jari Hartman; Seija Peltonen; Anders Albäck; Riitta Lassila
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

Review 9.  Secondary prevention strategies for coronary heart disease.

Authors:  Shepard D Weiner; LeRoy E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

10.  Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women.

Authors:  Muthuvel Jayachandran; Robert D Litwiller; Whyte G Owen; John A Heit; Thomas Behrenbeck; Sharon L Mulvagh; Philip A Araoz; Matthew J Budoff; S Mitchell Harman; Virginia M Miller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.